Business
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
– Patent Will Also Cover a Related Method of Production of the Material – – Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –
About this update from Immunic, Inc.
[{"type":"text","content":"– Patent Will Also Cover a Related Method of Production of the Material –\n– Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –\n– Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States and Into 2039 Internationally, Unless Extended Further –\nNEW YORK, March 20, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 16/981,122, entitled, \"Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,\" covering the composition-of-matter of a specific polymorph of vidofludimus calcium (IMU-838) and a related method of production of the material. The claims are expected to provide protection into 2039, unless extended further. The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.\n\"Allowance of this key composition-of-matter patent, covering the specific polymorph of vidofludimus calcium, provides another important layer of proprietary intellectual property protection around our lead, late-stage asset,\" stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. \"A significant part of this patent will also cover the related method of producing material of vidofludimus calcium used in our studies. Importantly, we meanwhile have eight patent families active for vidofludimus. Our commitment to protecting the technology behind this phase 3 asset remains paramount and is made that much stronger by the addition of this fourth U.S. patent directed to the use of vidofludimus calcium in multiple sclerosis.\"\nVidofludimus calcium is covered by several layers of granted patents in the United States, Europe and other jurisdictions around the world. These patents are directed towards composition-of-matter for salt forms of vidofludimus, including the specific calcium salt form used in Immunic's clinical trials; the treatment of relapsing multiple sclerosis with a specific dose strength used in the clinical trials; the dosing regimens, including those used in clinical trials for the treatme...